Xenon Pharmaceuticals (XENE) Total Liabilities (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Total Liabilities data on file, last reported at $49.0 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 24.59% year-over-year to $49.0 million in Q1 2026; TTM through Mar 2026 was $49.0 million, a 24.59% increase from a year earlier, with the FY2025 full-year figure at $51.4 million, up 18.89% from the prior year.
• Total Liabilities for Q1 2026 stood at $49.0 million, down from $51.4 million in the prior quarter.
• Over the last five years, Total Liabilities for XENE reached as high as $51.4 million in Q4 2025 and fell as low as $16.2 million in Q1 2022.
• Historically, Total Liabilities has averaged $36.3 million across 5 years, with a median of $38.1 million in 2024.
• Across the five-year window, Total Liabilities soared 103.16% in 2023 and dropped 4.86% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $32.6 million in 2022, then climbed by 12.95% to $36.9 million in 2023, then increased by 17.24% to $43.2 million in 2024, then advanced by 18.89% to $51.4 million in 2025, then retreated by 4.69% to $49.0 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $49.0 million in Q1 2026, $51.4 million in Q4 2025, and $48.3 million in Q3 2025.